Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$LGND Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.42 up 868.00% YoY • Reported revenue of $63.69M up 33.73% YoY • Ligand Pharmaceuticals is reaffirming its 2026 full-year revenue guidance and is raising the low end of its adjusted earnings per diluted share guidance range to approximately $9.00 to $9.50.

Price since post

Full Details